tbuckley/cabot-search huggingface dataset:
Immunogenicity, Safety, and Efficacy of a Standalone Universal Influenza Vaccine, FLU-v, in Healthy Adults
Authors: Olga Pleguezuelos, Joep Dille, Sofie de Groen, Fredrik Oftung, Hubert G.M. Niesters, Md Atiqul Islam, Lisbeth Meyer Næss, Olav Hungnes, Nuhoda Aldarij, Demi L. Idema, Ana Fernandez Perez, Emma James, Henderik W. Frijlink, Gregory Stoloff, Paul Groeneveld, Eelko Hak
Journal: Annals of Internal Medicine (2020)

Background: FLU-v is a broad-spectrum influenza vaccine that induces antibodies and cell-mediated immunity. Objective: To compare the safety, immunogenicity, and exploratory efficacy of different formulations and dosing regimens of FLU-v versus placebo. Design: Randomized, double-blind, placebo-controlled, single-center phase 2b clinical trial. (ClinicalTrials.gov: NCT02962908; EudraCT: 2015-001932-38) Setting: The Netherlands. Participants: 175 healthy adults aged 18 to 60 years. Intervention: 0.5-mL subcutaneous injection of 500 µg of adjuvanted (1 dose) or nonadjuvanted (2 doses) FLU-v (A-FLU-v or NA-FLU-v) or adjuvanted or nonadjuvanted placebo (A-placebo or NA-placebo) (2:2:1:1 ratio). Measurements: Vaccine-specific cellular responses at days 0, 42, and 180 were assessed via flow cytometry and enzyme-linked immunosorbent assay. Solicited information on adverse events (AEs) was collected for 21 days after vaccination. Unsolicited information on AEs was collected throughout the study. Results: The AEs with the highest incidence were mild to moderate injection site reactions. The difference between A-FLU-v and A-placebo in the median fold increase in secreted interferon-γ (IFN-γ) was 38.2-fold (95% CI, 4.7- to 69.7-fold; P = 0.001) at day 42 and 25.0-fold (CI, 5.7- to 50.9-fold; P < 0.001) at day 180. The differences between A-FLU-v and A-placebo in median fold increase at day 42 were 4.5-fold (CI, 2.3- to 9.8-fold; P < 0.001) for IFN-γ–producing CD4+ T cells, 4.9-fold (CI, 1.3- to 40.0-fold; P < 0.001) for tumor necrosis factor-α (TNF-α), 7.0-fold (CI, 3.5- to 18.0-fold; P < 0.001) for interleukin-2 (IL-2), and 1.7-fold (CI, 0.1- to 4.0-fold; P = 0.004) for CD107a. At day 180, differences were 2.1-fold (CI, 0.0- to 6.0-fold; P = 0.030) for IFN-γ and 5.7-fold (CI, 2.0- to 15.0-fold; P < 0.001) for IL-2, with no difference for TNF-α or CD107a. No differences were seen between NA-FLU-v and NA-placebo. Limitation: The study was not powered to evaluate vaccine efficacy against influenza infection. Conclusion: Adjuvanted FLU-v is immunogenic and merits phase 3 development to explore efficacy. Primary Funding Source: SEEK and the European Commission Directorate-General for Research and Innovation, European Member States within the UNISEC (Universal Influenza Vaccines Secured) project.
INFLUENCE OF SEX ON THE PROGNOSTIC IMPACT OF CARDIAC MAGNETIC RESONANCE IMAGING QUANTIFICATION OF FUNCTIONAL MITRAL REGURGITATION IN PATIENTS WITH NON-ISCHEMIC CARDIOMYOPATHY
Authors: Duygu Kocyigit, Nishant Shah, Jennifer Bullen, Sophia Downey, Nancy Obuchowski, Nathaniel Lee, W.H. Wilson Tang, Brian P. Griffin, Scott D. Flamm, Deborah Kwon
Journal: Journal of the American College of Cardiology (2020)
Desloratadine and loratadine use associated with improved melanoma survival
Authors: Ildikó Fritz, Philippe Wagner, Matteo Bottai, Hanna Eriksson, Christian Ingvar, Isabelle Krakowski, Kari Nielsen, Håkan Olsson
Journal: Allergy (2020)

Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
A neoadjuvant, randomized, open-label phase II trial of afatinib (A) versus trastuzumab (T) versus lapatinib (L) in patients (pts) with locally advanced HER2-positive breast cancer (BC).
Authors: Mothaffar F. Rimawi, Sabina B. Aleixo, Ashley Alarcon Rozas, Joao Nunes Matos Neto, Maira Caleffi, Jeferson J.F. Vinholes, Alicardo Cesar Figueira, Sulene Cunha Souza, Andre B. Reiriz, Heloisa Arantes, Martina Maria Uttenreuther-Fischer, C. Kent Osborne
Journal: Journal of Clinical Oncology (2012)

606 Background: A is an oral, irreversible, ErbB Family Blocker. This Phase II study investigated A, L and T monotherapy in pts with locally advanced HER2 (ErbB2)-positive BC in a 6-wk preoperative treatment window. Methods: This international, multi-institutional, open-label, randomized, Phase II study included pts with HER2-positive locally advanced disease Stage IIIa–c and inflammatory BC with no evidence of distant metastatic disease, at least one tumor lesion ≥5 cm in diameter, and an ECOG score 0–1. Pts agreed to fresh tumor biopsies for biomarker analyses at trial entry, and at 3 and 6 wks of treatment. Pts received 50 mg A once daily, 1500 mg L once daily, or T 2 mg/kg weekly after a loading dose of 4 mg/kg for 6 wks. Results: 73 pts were screened and 29 pts randomized and treated* (10 pts A, 8 pts L, 11 pts T). All pts were female, median age 49 (range 25–88) yrs, 28/29 pts had Stage III disease, 3/29 pts had inflammatory BC, median tumour size was 6.4 cm, and median time to treatment was 1.4 months (range 0–3.4). After 6 wks of treatment, OR was assessed using RECIST 1.0 (Table). Best objective response during treatment was 80%, 75%, and 36.4% in the pts treated with A, L, and T, respectively. Drug-related AEs assessed by CTCAE v.3.0 occurred in all pts treated with A, 75% of pts treated with L, and 45.5% of patients treated with T (largely GI and skin-related AEs for A and L, and GI and musculoskeletal AEs for T). Three pts treated with A and one pt with L had drug-related AEs of CTCAE Grade 3. Conclusions: Afatinib showed a high OR rate in this Phase II trial of a 6-wk preoperative treatment window and compared favorably to two approved agents in HER2-positive BC, albeit at a slightly higher rate of AEs. Further trials will be needed to identify the potential role of A as a single agent or in combination with other agents in HER2-positive BC. [Table: see text]
Bilateral testicular germ cell tumors (TGCT) prevalence: The 24-year-long single-center experience.
Authors: Marija Gamulin, Mislav Grgic, Lana Jajac Brucic
Journal: Journal of Clinical Oncology (2012)

e15031 Background: Theetiology andreliable biomarkers for the risk of bilateral TGCT are still under investigation. Long-term relapse risks of up to 20 years after the therapy in contralateral testes demand a specific model of surveillance. Due to the rarity of the tumor type, reports of national experiences of bilateral TGCT are of a crucial significance for a future global database. Methods: The study was conducted during the treatment of 1 823 patients with TGCT in a single center from 1987-2011. Their mean age was 24 years at the time of diagnosis. Results: Out of 1 823 patients diagnosed with TGCT, 33 developed the bilateral disease (1.81%), 11 of them had synchronous tumors (33%). In the rest of patients the second testicular tumor was diagnosed 1 to 17 years after the initial diagnosis. The mean age of patients with bilateral TGCT was 28. According to the histological type: 11 were seminoma, 14 non-seminoma and 8 mixed seminoma and non-seminoma. Seven patients with bilateral tumor had a seminoma component at initial diagnosis. Compared to 5 patients out of 11 with synchronous tumor, the yolk sac component was detected only in 2 out of 22 metachronous patients. Conclusions: The presented findings of bilateral TGCT prevalence (1.8%) are in concordance with similar previous studies. As this type of tumor may be effectively treated, the risk assessment of metachronous tumor development should in future be facilitated by new biomarkers based on omics techniques. Thus, the investigation of karyotyping, c-KIT and transcriptome specificities will contribute to elucidation which pathways contribute to germ cell neoplasms. The stem cell markers for pluripotency maintenance may in future become potential diagnostic markers used as predictors for metastatic germ cell tumors. The development of a global database on these rare tumors will be of a crucial importance.
A multicenter phase II randomized study of customized neoadjuvant therapy versus standard chemotherapy (CT) in non-small cell lung cancer (NSCLC) patients with resectable stage IIIA(N2) disease (CONTEST trial).
Authors: Francesco Grossi, Erika Rijavec, Giulia Barletta, Claudio Sini, Carlo Genova, Maria Giovanna Dal Bello, Giovanni Battista Ratto, Mauro Truini, Domenico Franco Merlo
Journal: Journal of Clinical Oncology (2013)

TPS7606 Background: Stage IIIA NSCLC constitutes 30% of all NSCLC patients (pts). The most powerful prognostic factor that has been identified in this stage is clearance of mediastinal lymph nodes and pathologic complete response (pCR). A pCR is obtained in 5-15% of pts with a significant survival prolongation. The identification of molecular biomarkers, such as excision repair cross-complementation 1 (ERCC1), ribonucleotide reductase subunit M1 (RRM1), and thymidylate synthase (TS), may predict response to CT. Similarly, EGFR mutations may predict response to EGFR inhibitors. Methods: CONTEST, a multicenter (19 Italian centers), randomized (2:1) 2-arm phase II study, recruits pts with resectable stage IIIA (N2) NSCLC. Pts will be randomized to receive before resection either standard CT with Cisplatin (CDDP) 75 mg/m 2 + Docetaxel (Doc) 75 mg/m 2 on day (d) 1 q 21 d for 3 cycles (cys) or customized therapy using predetermined values for ERCC1, RRM1, TS, and EGFR mutations. The choices of customized arms are as follows: -EGFR+: Gefitinib 250 mg/d for 8 weeks. -EGFR-/non-squamous (NS)/TS-/ERCC1-: CDDP 75 mg/m 2 + Pemetrexed 500 mg/m 2 d 1 q 21 d for 3 cys. -EGFR-/squamous (S) or NS TS+/ERCC1-/RRM1+: CDDP 75 mg/m 2 + Doc 75 mg/m 2 d 1 q 21 d for 3 cys. -EGFR-/S or NS TS+/ERCC1-/RRM1-: CDDP 75 mg/m 2 d 1+ Gemcitabine (Gem) 1250 mg/m 2 d 1,8 q 21 d for 3 cys. -EGFR-/S or NS TS+/ERCC1+/RRM1+: Doc 75 mg/m 2 d 1 + Vinorelbine 20 mg/m 2 d 1,8 q 21 d for 3 cys. -EGFR-/S or NS TS+/ERCC1+/RRM1-: Doc 40 mg/m 2 y 1, 8 + Gem 1200 mg/m 2 d 1,8 q 21 d for 3 cys. The primary end point will be obtained by comparing the pCR in all randomized pts based on treatment arm. Because pCR is a surrogate endpoint and given the expected proportion of pCR's in the control group pc= 5%, the minimal clinically worthwhile effect of this customized treatment is an increase in this proportion to 20%. To detect such an effect at the 0.05 (1-sided) significance level with 80% power, a total of 168 pts will be enrolled. This study is open for accrual; further details can be found on ClinicalTrials.gov (NCT01784549). Funded by Italian Ministry of Health – RF 2009-1530324. Clinical trial information: NCT01784549.
COMPARISON OF HEART, TIMI AND GRACE SCORES IN PREDICTING MAJOR ADVERSE CARDIAC EVENTS WITHIN 120 DAYS IN PATIENTS PRESENTING TO THE EMERGENCY DEPARTMENT WITH CHEST PAIN IN A COMMUNITY HEALTH SYSTEM
Authors: Luis Alonso Hernandez Mejia, Anmary Fernandez Betances, Manojna Nimmagadda, Sumit Sohal, Diana Miranda Ruiz, Beulah Jyothy Koduru, Carlos Marin Ramirez, Karen O'Connor Perla, Chukwudumebi Okafor, Ruchie Bhattarai, Luis Galindez, Ramon Checo, Dhiran Verghese
Journal: Journal of the American College of Cardiology (2020)
Association of Cardiac Rehabilitation With Survival Among US Veterans
Authors: Nirupama Krishnamurthi, David W. Schopfer, Hui Shen, Mary A. Whooley
Journal: JAMA Network Open (2020)

IMPORTANCEParticipation in cardiac rehabilitation (CR) programs at Veterans Affairs (VA) facilities is low.Most veterans receive CR through purchased care at non-VA programs.However, limited literature exists on the comparison of outcomes between VA and non-VA CR programs.OBJECTIVE To compare 1-year mortality and 1-year readmission rates for myocardial infarction or coronary revascularization between VA vs non-VA CR participants.DESIGN, SETTING, AND PARTICIPANTS This cohort study included 7320 patients hospitalized for myocardial infarction or coronary revascularization at the VA between 2010 and 2014 who did not die within 30 days of discharge and who participated in 2 or more CR sessions after discharge.The study excluded individuals hospitalized for ischemic heart disease after December 2014 when the VA Choice Act changed referral criteria for non-VA care.Data analysis was performed from November 2019 to January 2020.EXPOSURES Participation in 2 or more CR sessions within 12 months of discharge at a VA or non-VA facility. MAIN OUTCOMES AND MEASURESThe 1-year all-cause mortality and 1-year readmission rates for myocardial infarction or coronary revascularization from date of discharge were compared between VA vs non-VA CR participants using Cox proportional hazards models with inverse probability treatment weighting. RESULTSThe 7320 veterans with ischemic heart disease who participated in CR programs had a mean (SD) age of 65.13 (8.17) years and were predominantly white (6005 patients [82.0%]), non-Hispanic (6642 patients [91.0%]), and male (7191 patients [98.2%]).Among these 7320 veterans, 2921 (39.9%) attended a VA facility, and 4399 (60.1%) attended a non-VA CR facility.Black and Hispanic veterans were more likely to attend CR programs at VA facilities (509 patients [17.4%] and 378 patients [12.9%], respectively), whereas white veterans were more likely to attend CR programs at non-VA facilities (3759 patients [85.5%]).After inverse probability treatment weighting, rates of 1-year mortality were 1.7% among VA CR participants vs 1.3% among non-VA CR participants (hazard ratio, 1.32; 95% CI, 0.90-1.94;P = .15).Rates of readmission for myocardial infarction or revascularization during the 12 months after discharge were 4.9% among VA CR participants vs 4.4% among non-VA CR participants (hazard ratio, 1.06; 95% CI, 0.83-1.35;P = .62). CONCLUSIONS AND RELEVANCEThese findings suggest that rates of 1-year mortality and 1-year readmission for myocardial infarction or revascularization did not differ for participants in VA vs non-VA cardiac rehabilitation programs.Eligible patients with ischemic heart disease should participate in CR programs regardless of where they are provided.
Prevalence of antibiotic resistant strains in fecal surveillance cultures of patients from a new tertiary care cancer center in eastern part of India.
Authors: Vivek Sulekha Radhakrishnan, Gaurav Goel, Dipmala Das, Sriram Ravichandran, Vishvdeep Khushoo, Saurabh Jayant Bhave, Anupam Chakrapani, Reena Nair, Sanjay Bhattacharya, Mammen Chandy
Journal: Journal of Clinical Oncology (2013)

e20686 Background: Drug resistant organisms are a very common cause of infections in critically ill patients in India. Surveillance Cultures is part of a multi-factorial approach to control MDRO[Multi-Drug Resistant Organisms]. Colonization surveillance may have the potential to improve empiric antimicrobial treatment in a critical care setting. Methods: Design: Retrospective. Setting: Newly started Comprehensive Cancer Center in Eastern part of India. Period: Dec 2011 - Jan 2013. Review of fecal surveillance cultures of patients undergoing intensive chemotherapy for hematological cancers or haemopoietic stem cell transplant. Fecal Surveillance cultures were done prior to Intensive Chemotherapy using a method based on Landman D et al (J Clin Microbiol 2005). Results: 48 patients [35 male,13 female] admitted with diagnoses of AML(22), ALL(6), APL(1), Acute Mixed Lineage Leukemia(1), MDS(1), Hodgkin Lymphoma(1), DLBCL(1), Fanconi Anemia(1), Multiple Myeloma(4), and Myeloproliferative Disorder(1) had information on Fecal Surveillance Cultures. Mean age: 35yrs [range; Male: 6-67yrs, Female:10-59yrs]. Total Samples collected: 67. Median sample per pateint: 1(range 1-4). All samples excepting one, grew MDRO isolates (98.5%). No. of Isolates:136 [95 gram negative bacilli (GNB), 41 gram positive cocci (GPC)]. Among GPC isolates, resistance to Ampicillin, Vancomycin, High level Gentamycin, and Linezolid were 86.5% (32/37), 7.3%(3/41), 60.9%(25/41) and nil(0/41) respectively. Among GNB isolates, resistance to Cefotaxime, Ciprofloxacin, Co-Amoxiclav, Gentamycin, Amikacin, Piperacillin-Tazobactum, Meropenem and Colistin were respectively 90.8%(79/87), 67.4%(60/89), 67.4%(60/89), 45.2%(43/95), 23.4%(22/94), 39.7%(37/93), 25.8%(24/93) and 6.4%(5/78). In the coliform group, the prevalence of ESBL/Amp-C producing isolates was 91.7%. Carbapenamase production was noted in 25.8% of GNB isolates. Conclusions: There is a very high prevalence of background antimicrobial resistance in the enteric flora of patients receiving intensive chemotherapy at our center. The causes of widespread MDRO in our setting needs further studies.
Comparison of pain and efficacy between large-bore and small-bore chest tube drainage for malignant pleural effusion in Songklanagarind Hospital: A randomized controlled trial.
Authors: Apirudee Porntepkasemson, Sarayut Lucien Geater
Journal: Journal of Clinical Oncology (2012)

e19608 Background: Malignant pleural effusion is one of the most common presenting symptoms in lung cancer. There has been no large RCT comparing large-bore and small-bore chest tubes in terms of pain and efficacy of management. Methods: A randomized controlled trial was conducted in 2011. Patients with malignant pleural effusion were randomly allocated to receive either a large-bore or small-bore chest tube. The primary objective was to compare pain using the Numeric Rating Scale. Other objectives included the efficacy of the drainage and pleurodesis and any complications were recorded. Results: Each arm comprised 21 patients. Median age was 61.2 years. Thirty-eight patients (90.5%) had adenocarcinoma; 14(33.3%) had received systemic chemotherapy. Pain score did not differ significantly between the groups from the time of tube insertion to removal. However, pain rose from day 4 until day 9 in the small-bore group. The proportion of patients requiring a second chest tube was higher in the small-bore group (small-bore = 7, 33.3 %; large-bore = 1, 4.8%; p 0.052). Complications were higher in the small-bore group. Five patients were complicated by tube occlusion which occurred only in the small-bore group (23.8 %, p 0.048). Times from tube insertion to lung expansion, to pleurodesis and to chest tube removal did not differ significantly between groups. Pleurodesis was effective in 70-80 % in both groups at the 28-day follow-up. Conclusions: No differences between large-bore and small-bore chest tubes were seen in pain, efficacy of drainage or success of pleurodesis. However, small-bore chest tubes had a higher rate of occlusion and more frequently required additional tube insertion.
ANTICOAGULANT THERAPY FOR VENOUS THROMBOEMBOLISM AFTER DIRECT ORAL ANTICOAGULANT INTRODUCTION IN REAL-WORLD SETTINGS
Authors: Ryuki Chatani, Reo Hata, Ryosuke Murai, Hidewo Amano, Yuichi Kawase, Takeshi Tada, Kazushige Kadota
Journal: Journal of the American College of Cardiology (2020)
FACTORS ASSOCIATED WITH TOLERABILITY OF SACUBITRIL-VALSARTAN IN ICU PATIENTS WITH LOW CARDIAC OUTPUT
Authors: Trejeeve Martyn, Kathleen Faulkenberg, Chonyang Albert, Dmitry Yaranov, Zachary Il'Giovine, Rob Montgomery, Jerry D. Estep, Venu Menon, Wai Hong Wilson Tang, Randall C. Starling
Journal: Journal of the American College of Cardiology (2020)
A COMBINATION OF FRAILTY AND RENAL DYSFUNCTION DETERIORATES CLINICAL OUTCOMES IN PATIENTS WITH ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION
Authors: Masanari Kurobe, Jun Yonekawa, Akinori Satake, Yuichiro Makino, Koji Mizutani, Yoshiaki Mizutani, Hitoshi Ichimiya, Yasuhiro Uchida, Junji Watanabe, Masaaki Kanashiro, Hideki Ishii, Tetsuya Amano, Tatsuaki Matsubara, Satoshi Ichimiya, Toyoaki Murohara
Journal: Journal of the American College of Cardiology (2020)
Abstract 18207: Propensity-Matched Comparison of Outcomes of Coronary Artery Bypass Grafting versus Percutaneous Coronary Intervention Using Second Generation Drug Eluting Stents for Multivessel Coronary Artery Disease
Authors: Vasileios Panoulas, Habib Khan, Sanjay Chaubey, Ian Cummings, Charles J Ilsley, Shahzad G Raja
Journal: Circulation (2017)

Introduction: There is limited data comparing percutaneous coronary intervention (PCI) using second generation drug eluting stents (DES) with coronary artery bypass grafting (CABG) for treatment of...
ACQUISITION OF DIAGNOSTIC ECHOCARDIOGRAPHIC IMAGES BY NOVICES USING A DEEP LEARNING BASED IMAGE GUIDANCE ALGORITHM
Authors: Akhil Narang, Richard Bae, Ha Hong, Yngvil Thomas, Sam Surette, Charles Cadieu, Ali Chaudhry, Randolph Martin, David S. Rubenson, Steven A. Goldstein, Stephen Henry Little, Roberto Lang, Neil J. Weissman, James Thomas
Journal: Journal of the American College of Cardiology (2020)
Intra-carotid chemo (ICC) followed by radiation (RT) with concomitant temozolamide (TMZ) and subsequent maintenance TMZ therapy in patients (pts) with glioblastoma multiforme (GBM)
Authors: G. Mohin, R. Davis, A. Meek, A. Rosiello, C. Roque, P. Hentschel, P. Roche, J. Manzione, J. Vacirca, S. Madajewicz
Journal: Journal of Clinical Oncology (2006)

1554 Background: Glioblastoma multiforme is one of the most resistant malignant tumors. Surgery provides only temporary, palliative relief. Radiation therapy affords additional, though short, benefit. Systemic, intravenous and/or oral chemotherapy with nitrosoureas and TMZ, increases survival only slightly. Median survival (MS) after all these modalities incorporated remains unimpressive, less than 14 months. Intracarotid chemotherapy with cisplatin and VP-16, a standard treatment at Stony Brook University Hospital since 1999, prior to RT, results in MS of 20 months. A year later we added TMZ as a part of standard treatment with or without ICC in patients with GBM. Provided here is a retrospective analysis of the treatment consisting of surgery, ICC, RT with concomitant TMZ followed by 2 years of TMZ maintenance. Methods: Fifteen patients with pathologically confirmed, newly diagnosed GBM were treated from year 2000 to 2005; 11 men; median age 53 (range 25-68); 80% with PS over 70. They underwent a surgical procedure (5 near total) followed by ICC with cisplatin 60 mg/m 2 and VP-16 40 mg/m 2 every 3 weeks for total of 3 cycles. Subsequently they received TMZ 75 mg/m 2 /day orally, concomitantly with RT 6120–6300 cGY, followed a month later by maintenance therapy with TMZ 200 mg/m 2 / daily for 5 days out of each month for 2 years or until progression. Results: Fourteen pts.are being evaluated (one too early), all have survived at least 12 months.One-year PFS is 79%. Median time to progression is 19.5 months; MS is 25 months with a range of 12-48 months. Toxicity is limited to nausea and vomiting mainly grade 1-2; only 1 patient experienced grade 3 vomiting with subsequent TMZ maintenance dose reduction by about 10%. Conclusions: Surgery followed by ICC, then combination of RT + TMZ followed by maintenance TMZ therapy seems to be more effective in improving patient survival than surgery, ICC and RT as reported previously by us in pts with GBM (Cancer 2000; 10:2350–6). This treatment has been well tolerated. No significant financial relationships to disclose.
LMCA ACUTE OCCLUSION AND STEMI WITH CARDIOGENIC SHOCK REQUIRING ADVANCED HEMODYNAMIC SUPPORT
Authors: Balda Javier, Artem Astsaturov, Rizwan Khan, Maheswara Satya Golla, Joseph Patrick Carrozza, Lana Tsao, Lawrence A. Garcia
Journal: Journal of the American College of Cardiology (2020)
Comparison of Preliminary clinical outcomes between percutaneous endoscopic and minimally invasive transforaminal lumbar interbody fusion for lumbar degenerative diseases in a tertiary hospital: Is percutaneous endoscopic procedure superior to MIS-TLIF? A prospective cohort study
Authors: Shengxiang Ao, Wenjie Zheng, Junlong Wu, Yu Tang, Chao Zhang, Yue Zhou, Changqing Li
Journal: International Journal of Surgery (2020)
EFFECT OF BASELINE LEFT VENTRICULAR EJECTION FRACTION ON FUTURE CLINICAL OUTCOMES IN A REAL-WORLD POPULATION OF PATIENTS WITH HEART FAILURE: HOW EXACTLY DOES HFREF COMPARE WITH HFPEF?
Authors: J. Brent Muhlestein, Jennifer Kammerer, Tami Bair, Kirk Knowlton, Viet T. Le, Jeffrey L. Anderson, Donald Lappe, Heidi May
Journal: Journal of the American College of Cardiology (2020)